



Published in final edited form as:

*J Invest Dermatol.* 2012 June ; 132(6): 1656–1664. doi:10.1038/jid.2012.16.

## $\gamma\delta$ T cells augment rejection of skin grafts by enhancing cross priming of CD8 T cells to skin derived antigen

Azad Rahimpour<sup>1,2</sup>, Stephen R Mattarollo<sup>1,3</sup>, Michelle Yong<sup>1</sup>, Graham R Leggatt<sup>1</sup>, Raymond J Steptoe<sup>1</sup>, and Ian H Frazer<sup>1</sup>

<sup>1</sup>The University of Queensland Diamantina Institute, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia, 4102

<sup>2</sup>Department of Microbiology and Immunology, The University of Melbourne, Melbourne, Victoria, Australia, 3010

<sup>3</sup>Cancer Immunology Program, Peter MacCallum Cancer Center, East Melbourne, Victoria, Australia, 3002

### Abstract

$\gamma\delta$  T cells possess innate like properties and are proposed to bridge the gap between innate and adaptive immunity. In this study we explored the role of  $\gamma\delta$  T cells in cutaneous immunity utilizing a skin transplantation model. Following engraftment of skin expressing cell associated model antigen (ovalbumin) in epithelial keratinocytes, skin resident  $\gamma\delta$  T cells enhanced graft rejection. While effector function of CD8 T cells was intact in the absence of  $\gamma\delta$  T cells, cross priming of CD8 T cell to graft derived antigen was impaired in the absence of  $\gamma\delta$  T cells. The reduced graft rejection and graft priming of  $\gamma\delta$  T cell deficient mice was evident in both acutely inflamed and well-healed grafting models. Furthermore, expression of the CD40 activation marker on migrating dendritic cells was lower in TCR $\delta$ <sup>-/-</sup> mice compared to wildtype mice, regardless of the presence or absence of inflammation associated with grafting. These results indicate that  $\gamma\delta$  T cells enhance graft priming and consequently the likelihood of a successful immune outcome in the context of skin graft rejection suggesting that  $\gamma\delta$  T cells may be an important component of immunity to epithelial cancers or infection.

### INTRODUCTION

$\gamma\delta$  T cells are a minor subpopulation of T cells in the circulation, however they are highly enriched in epithelial tissues such as skin, gut, lungs and the genitourinary tract (Allison and Havran, 1991).  $\gamma\delta$  T cell deficient (TCR $\delta$ <sup>-/-</sup>) mice have perturbed epithelial physiology and immune responsiveness upon various biological and non-biological challenges. A skin-resident subset of  $\gamma\delta$  T cells called dendritic epidermal T cells (DETC) plays a critical role in tumor surveillance following treatment of skin with dimethylbenzanthracene (DMBA) and

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:[http://www.nature.com/authors/editorial\\_policies/license.html#terms](http://www.nature.com/authors/editorial_policies/license.html#terms)

Corresponding Author: Ian Frazer P: + 61-7-32405832 F: +61-7-32405946 i.frazer@uq.edu.au.

**CONFLICT OF INTEREST** The authors declare no conflict of interest.

tetradecanoylphorbol (TPA) (Girardi *et al.*, 2001). The intestinal tract of TCR $\delta$ <sup>-/-</sup> mice has been shown to exhibit increased immunopathology and epithelial damage following infection with *Eimeria vermiformis* or treatment with dextran sodium sulphate (DSS) in a DSS-induced model of mouse colitis (Chen *et al.*, 2002; Roberts *et al.*, 1996). Ozone treatment and infection with *Nocardia asteroides* results in increased pulmonary damage and high lethality in  $\gamma\delta$  T cell deficient mice (King *et al.*, 1999). In the kidneys, the severity of adriamycin-induced nephropathy is dampened by intraepithelial  $\gamma\delta$  T cells (Wu *et al.*, 2007).

Notwithstanding the fact that the majority of research on intraepithelial  $\gamma\delta$  T cells has been on the role of  $\gamma\delta$  cells in cutaneous immunity, our understanding of the involvement of  $\gamma\delta$  T cells in the immune processes in the skin is incomplete. While the role of skin resident  $\gamma\delta$  T cells in tumor surveillance, wound healing and homeostasis in the skin has been elaborately described (Girardi *et al.*, 2001; Jameson and Havran, 2007; Jameson *et al.*, 2002; Sharp *et al.*, 2005), the details of how skin resident  $\gamma\delta$  T cells regulate the function of other skin associated immune cells have not been extensively studied. For example the effects of  $\gamma\delta$  T cells on cross-presentation of skin derived Ag in generating adaptive immune responses is largely unknown.

Skin transplantation has been used in research as a model to study histocompatibility, cutaneous immunity and the pathophysiology of solid organ transplant rejection (Klein, 1975; Rosenberg and Singer, 1992). The paradigm of skin graft rejection involves the presentation of skin-derived antigens by Ag presenting cells in the lymph node to CD4 and CD8 T cells, which subsequently results in the generation of adaptive immune responses (Lakkis *et al.*, 2000; Rosenberg *et al.*, 1987; Sawada *et al.*, 1997). The role of skin resident  $\gamma\delta$  T cells in this process has not been described. This study describes the role of  $\gamma\delta$  T cells in rejection of ovalbumin (OVA) expressing skin grafts. We show that skin resident  $\gamma\delta$  T cells enhance skin graft rejection. We also show that while cross-priming of CD8 T cells to Ag delivered subcutaneously in conjunction with an adjuvant is intact in TCR $\delta$ <sup>-/-</sup> mice, cross-priming to skin derived Ag is impaired in  $\gamma\delta$  T cell deficient mice in both acutely inflamed and well-healed skin grafts. Furthermore, we show that while trafficking of skin derived dendritic cells is not impaired in  $\gamma\delta$  T cell deficient mice, the expression of the CD40 co-stimulatory molecule on migrating DCs is lower in transplanted and naive TCR $\delta$ <sup>-/-</sup> mice compared to wildtype. Therefore we describe a novel role for  $\gamma\delta$  T cells in cutaneous immunity.

## RESULTS

### Skin resident $\gamma\delta$ T cells enhance rejection of ovalbumin-expressing skin grafts

Immunocompetent mice reject otherwise syngeneic skin expressing OVA in keratinocytes from a keratin 5 promoter (K5mOVA mice) (Azukizawa *et al.*, 2003). To establish the contribution of  $\gamma\delta$  T cells to skin graft rejection, we generated TCR $\delta$ <sup>-/-</sup>-OVA<sup>+/-</sup> mice by crossing TCR $\delta$ <sup>-/-</sup> (C57BL/6 strain) and K5mOVA (C57BL/6 strain) mice. TCR $\delta$ <sup>-/-</sup> mice were double grafted with skin from TCR $\delta$ <sup>-/-</sup> (control) and TCR $\delta$ <sup>-/-</sup>-OVA<sup>+/-</sup> mice and the rejection rate was compared to that of C57BL/6 (control) and K5mOVA grafts by wildtype C57BL/6 mice. Control grafts in both groups were accepted indefinitely and while 100% of

K5mOVA grafts were rejected promptly by C57BL/6 mice as previously described, only 64% of TCR $\delta$ <sup>-/-</sup>-OVA<sup>+/-</sup> grafts were rejected by TCR $\delta$ <sup>-/-</sup> mice (Fig. 1A).

To clarify whether donor or host  $\gamma\delta$  T cells were contributing to rejection of OVA grafts, K5mOVA skin was transplanted onto TCR $\delta$ <sup>-/-</sup> mice, eliminating host  $\gamma\delta$  T cells and TCR $\delta$ <sup>-/-</sup>-OVA<sup>+/-</sup> skin (devoid of donor  $\gamma\delta$  T cells) was grafted onto wildtype mice. In both groups 100% of grafts were rejected robustly by their respective recipients, suggesting the presence of  $\gamma\delta$  T cells in either the donor or the recipient is sufficient for skin graft rejection and both must be absent for prolonged survival. Robust rejection of K5mOVA grafts by TCR $\delta$ <sup>-/-</sup> mice shows that in this model circulating  $\gamma\delta$  T cells are redundant and that skin resident  $\gamma\delta$  T cells enhance rejection of OVA expressing skin grafts (Fig. 1B). To confirm that skin rather than circulating  $\gamma\delta$  T cells were responsible for enhanced rejection, TCR $\delta$ <sup>-/-</sup> mice were grafted with TCR $\delta$ <sup>-/-</sup>-OVA<sup>+/-</sup> transgenic skin and were administered splenocytes from wildtype or TCR $\delta$ <sup>-/-</sup> animals (one donor spleen per recipient). No difference in the rate of graft rejection was observed (Fig. 1C), further confirming the finding that circulating  $\gamma\delta$  T cells do not contribute to graft rejection in this model.

### Impaired CD8 T cell priming to acutely inflamed graft-derived Ag in TCR $\delta$ <sup>-/-</sup> mice

Skin graft rejection generally requires priming of CD8 T cells to graft-derived Ag and generation of an Ag-specific effector T cell response (Rosenberg *et al.*, 1987; Rosenberg and Singer, 1992; Tak W. Mak, 2006). To determine whether  $\gamma\delta$  T cells contributed to the priming phase, wildtype and TCR $\delta$ <sup>-/-</sup> mice were transplanted with K5mOVA and TCR $\delta$ <sup>-/-</sup>-OVA<sup>+/-</sup> skin grafts respectively. Twenty days post-grafting, spleens were taken and OVA specific IFN $\gamma$  secreting CD8 T cell responses were assessed by IFN $\gamma$  ELISPOT stimulated with the cognate Ag SIINFEKL. Mean ELISPOT number for TCR $\delta$ <sup>-/-</sup> recipients was significantly lower than for C57 mice (Fig. 2A). IFN $\gamma$  was undetectable from splenic CD8 T cells of TCR $\delta$ <sup>-/-</sup> mice that had not rejected their skin grafts (data not shown), suggesting that acquisition of the capacity to reject a skin graft correlated with acquisition of effector function by Ag-specific CD8 T cells. To confirm this finding *in vivo*, OVA specific T cell proliferation was assessed by transfer of CFSE labeled Ly5.1<sup>+</sup> OT-I cells into wildtype and TCR $\delta$ <sup>-/-</sup> mice, that were thereafter transplanted with TCR $\delta$ <sup>+/-</sup>-OVA<sup>+/-</sup> and TCR $\delta$ <sup>-/-</sup>-OVA<sup>+/-</sup> grafts respectively. Nine days post-grafting, mean proliferation index of adoptively transferred OT-I cells was higher in graft DLNs of wildtype mice indicating faster proliferation in wildtype mice compared to  $\gamma\delta$  T cell deficient mice (Fig. 2B).

To determine whether the abrogation in CD8 T cell priming was a systemic defect in TCR $\delta$ <sup>-/-</sup> mice or a phenomenon seen only in priming to skin graft-derived Ag, wildtype and TCR $\delta$ <sup>-/-</sup> mice were immunized SC with OVA and QuilA. IFN $\gamma$  production by splenic CD8 T cells harvested after 7 days and re-challenged *in vitro* with SIINFEKL was comparable between wildtype and TCR $\delta$ <sup>-/-</sup> mice (Fig. 2C). Similarly, *in vivo* proliferation of adoptively transferred CFSE labeled Ly5.1<sup>+</sup> OT-I cells in DLNs after OVA and QuilA immunization was comparable between wildtype and TCR $\delta$ <sup>-/-</sup> mice (Fig. 2D). These results indicate that CD8 T cell priming in the absence of  $\gamma\delta$  T cells is impaired only when Ag expression is restricted to epithelial cells of the skin.

### Intact effector CD8 T cell function in TCR $\delta$ <sup>-/-</sup> mice

As  $\gamma\delta$  T cells were shown to be important in CD8 T cell priming to skin grafts, we examined whether they were also important in the effector phase of the immune response in skin graft rejection. Wildtype and TCR $\delta$ <sup>-/-</sup> mice were pre-immunized with OVA and QuilA and 7 days later each group was transplanted with their relevant OVA expressing grafts (K5mOVA onto C57BL/6 and TCR $\delta$ <sup>-/-</sup>-OVA<sup>+/-</sup> onto TCR $\delta$ <sup>-/-</sup>). All grafts were rejected by day 9 post grafting (Fig. 3A), suggesting that Ag-specific effector functions necessary for skin graft rejection were not significantly impaired in OVA primed mice lacking  $\gamma\delta$  T cells.

To confirm this finding, RAG/2CTCR Tg mice which lack OVA specific CD8 and  $\gamma\delta$  T cells (Sha *et al.*, 1988) were transplanted with either K5mOVA or TCR $\delta$ <sup>-/-</sup>-OVA<sup>+/-</sup> skin grafts and simultaneously administered  $1 \times 10^3$  *in vitro* activated OT-I cells which have been previously shown to be necessary and sufficient to enable rejection K5mOVA grafts from a T cell deficient mouse (Broom *et al.*; Kenna *et al.*, 2008). In both groups recipient mice rejected all skin grafts in a median time of 11 days (Fig. 3B), confirming that effector functions necessary for skin graft rejection are not impaired in the absence of  $\gamma\delta$  T cells.

### Impaired CD8 T cell priming to well-healed graft derived Ag in TCR $\delta$ <sup>-/-</sup> mice

CD8 T cell priming to OVA Ag by freshly placed K5mOVA grafts was impaired in the absence of  $\gamma\delta$  T cells (Fig. 2A, 2B). To determine whether the local inflammation associated with grafting which contributes to effective priming to skin graft associated Ag (Zhong *et al.*, 2008), is influenced by  $\gamma\delta$  T cells, we first examined the proliferation of CFSE labeled OT-I cells transferred into TCR $\delta$ <sup>+/-</sup>-OVA<sup>+/-</sup> or TCR $\delta$ <sup>-/-</sup>-OVA<sup>+/-</sup> mice. 42 hours post-transfer, significantly more OT-I cell proliferation was observed in the skin DLNs of  $\gamma\delta$  T cell replete mice (Fig. 4A).

In a second approach, wildtype and TCR $\delta$ <sup>-/-</sup> mice were transplanted with TCR $\delta$ <sup>+/-</sup>-OVA<sup>+/-</sup> and TCR $\delta$ <sup>-/-</sup>-OVA<sup>+/-</sup> skin grafts respectively. All recipient mice were initially treated with a CD8 $\beta$  depleting antibody to deplete CD8 T cells and therefore initially prevent skin graft rejection in the acute inflammatory phase. Graft rejection was monitored until day 90 by which time CD8 T cells had recovered. Whilst nearly 50% of grafts were rejected in the wildtype group, graft rejection was completely absent in the  $\gamma\delta$  T cell deficient group (Fig. 4B). At day 90, mice that had not rejected their skin grafts were injected with CFSE labeled OT-I cells to determine the proliferation rate of OT-I cells in the presence or absence of  $\gamma\delta$  T cells. Graft DLNs were taken 42 hours later and proliferation of OT-I cells was analyzed. Proliferation of OT-I cells was slower in the absence of  $\gamma\delta$  T cells compared to that in their presence (Fig. 4C). These data suggest that inflammation associated with skin grafting enhances T cell priming and graft rejection and in the absence of inflammation, skin graft rejection is further impaired in TCR $\delta$ <sup>-/-</sup> mice. This highlights the potential relevance of  $\gamma\delta$  T cells in general physiological or chronic inflammatory cutaneous settings in addition to their role in acutely inflamed transplantation model.

### Maturation, but not trafficking of migrating DCs is impaired in TCR $\delta$ <sup>-/-</sup> mice

Wound healing and macrophage infiltration into skin is impaired in TCR $\delta$ <sup>-/-</sup> mice (Jameson *et al.*, 2002; Jameson *et al.*, 2005). To assess whether the absence of  $\gamma\delta$  T cells could affect

the migration of skin associated dendritic cells and therefore influence cross-priming of CD8 T cells, we assessed DC migration to lymph nodes in wildtype and TCR $\delta$ <sup>-/-</sup> mice. We observed no differences in the migrating capacity of MHC-II<sup>hi</sup> CD11c<sup>hi</sup> DCs to DLNs following FITC painting of syngeneically grafted or non-grafted wildtype and TCR $\delta$ <sup>-/-</sup> skin (Fig. 5A).

In a second approach, TCR $\delta$ <sup>-/-</sup> mice were bred with Ly5.1<sup>+</sup> Ptpcrca mice to create congenically marked TCR $\delta$ <sup>-/-</sup> mice. Ly5.2<sup>+</sup> C57BL/6 and Ly5.2<sup>+</sup> TCR $\delta$ <sup>-/-</sup> mice were transplanted with Ly5.1<sup>+</sup> C57BL/6 and Ly5.1<sup>+</sup> TCR $\delta$ <sup>-/-</sup> skin. Four days post transplantation, Ly5.1<sup>+</sup> migrating skin DC populations were assessed in the DLNs and found to be similar between wildtype and TCR $\delta$ <sup>-/-</sup> mice (Fig. 5B).

Having observed no differences in the migration pattern of skin DCs, the activation state of migrating DCs was subsequently assessed by expression of CD40 co-stimulatory molecule on DCs from non-grafted and syngeneically grafted wildtype and TCR $\delta$ <sup>-/-</sup> mice. Modest but consistently lower levels of CD40 expression were observed in non-grafted and grafted TCR $\delta$ <sup>-/-</sup> mice when compared with non-grafted and grafted wildtype mice, indicating that maturation of DCs may be impaired in the absence of  $\gamma\delta$  T cells (Fig. 5C).

## DISCUSSION

In this study we demonstrate that skin resident  $\gamma\delta$  T cells enhance rejection of skin grafts expressing cell-associated (OVA). While the replacement  $\alpha\beta$  T cells present in the epidermis of TCR $\delta$ <sup>-/-</sup> mice cannot compensate for the lack of skin resident  $\gamma\delta$  T cells, a contribution by recently described dermal  $\gamma\delta$  T cells (Gray *et al.*, 2011; Sumaria *et al.*, 2011) to graft rejection cannot be ruled out. Furthermore we show that cross-presentation of Ag in the context of skin grafts is impaired in TCR $\delta$ <sup>-/-</sup> mice and this phenomenon is evident in both acute and well-healed grafts. In the same context optimal graft rejection is observed when priming by grafts is bypassed and achieved by systemic immunization.

In contrast, evidence in the literature, suggests a mainly down-regulatory and anti-inflammatory role for  $\gamma\delta$  T cells in various models (D'Souza *et al.*, 1997; Mombaerts *et al.*, 1993; Mukasa *et al.*, 1995; Shiohara *et al.*, 1996). Based on the studies published by Gorczynski *et al* on the role of  $\gamma\delta$  T cells limiting the rejection of small intestinal allografts (Gorczynski *et al.*, 1997; Gorczynski *et al.*, 1996), the authors originally hypothesized that in TCR $\delta$ <sup>-/-</sup> mice there would be an exacerbated immune response to skin grafts and graft rejection would take place more rapidly than in wildtype mice. The different outcome in the current work from that found by others (Gorczynski, 1994) may reflect the micro-anatomical restriction of the antigen to the epidermis in our model. As a result of this restriction, only cross priming by professional APC can lead to priming of the host animal as opposed to a mixture of cross and direct priming in allograft settings. Advantageously, this reductionist system breaks down the process of priming and focuses merely on cross priming by professional APC.

$\gamma\delta$  T cells lack TCR diversity and are proposed to recognize evolutionary conserved self molecules that may be up-regulated following stress (Hayday, 2000), therefore any

contribution by  $\gamma\delta$  T cells to skin graft rejection cannot be mediated directly by an Ag-specific response to the expression of OVA in skin grafts. DETCs can exert direct cytotoxic effects on transformed, stressed and cancerous keratinocytes, which express NKG2D ligands or unknown V $\gamma$ 3 TCR ligands *in vivo* and *in vitro* (Havran *et al.*, 1991; Kaminski *et al.*, 1993; Nitahara *et al.*, 2006). The relevance of this is highlighted by the expression of NKG2D ligand on skin grafts acutely after skin transplantation (Kim *et al.*, 2007). However the significance of any potential  $\gamma\delta$  T cell cytotoxicity in direct effector function against stressed OVA expressing skin grafts is reduced by the observation that  $\gamma\delta$  T cells are redundant in the effector phase of graft rejection in our model as pre-immunization against OVA protein prior to transplantation abrogates any defect seen in rejection in TCR $\delta$ <sup>-/-</sup> mice.

$\gamma\delta$  T cells can contribute to skin graft rejection through the production of cytokines, which in turn may enhance the priming phase of the immune response. *In vitro* studies have revealed a capacity for DETC to produce a multitude of cytokines such as TNF- $\alpha$ , GM-CSF and IFN- $\gamma$  (Boismenu *et al.*, 1996; Matsue *et al.*, 1993). However the basal levels or the triggers of heightened cytokine production by DETCs *in vivo* have not been fully described.

Furthermore the necessity, redundancy or usefulness of such cytokines produced by DETC in priming has not been studied *in vivo*. Induction of Rae-1 -a stress molecule and NKG2D ligand selectively in the epidermal compartment of the skin has been reported to result in activation of DETCs, morphological changes in DETCs and Langerhans cells and a modest up-regulation of CD86 on Langerhans cells (Strid *et al.*, 2008). While the up-regulation of CD86 and the change of cell shape in Langerhans cells is clearly an indirect effect of Rae-1 expression, no functional changes by Langerhans cells in relation to Ag presentation after the induction of Rae-1 expression was reported. Also it is not clear whether these changes were caused by DETC activation or by the infiltration of other NKG2D<sup>+</sup> cells to the skin. Based on the expression of NKG2D ligand in skin grafts we found that DETCs at a heightened level of activation five days after grafting evidenced by higher than baseline CD69 expression (data not shown). Inflammation induced Rae-1 expression and subsequent DETC activation may play a role in augmentation of graft rejection. However  $\gamma\delta$  T cells also enhance rejection of well-healed grafts without evidence of inflammation, thus, there may be multiple mechanisms through which  $\gamma\delta$  T cells can contribute to enhanced priming to Ag expressed in grafted skin including cytokines produced by non-activated DETC.

One possible mechanism considered for  $\gamma\delta$  T cells mediated enhancement of rejection was that, in their absence, there was defective migration of DCs from skin to DLNs. This hypothesis was based on the delay that is known to exist in the infiltration of macrophages into wounds and healing of wounds in the skin of  $\gamma\delta$  deficient mice (Jameson *et al.*, 2002; Jameson *et al.*, 2005). This hypothesis was dismissed using FITC painting and migration of congenically marked (Ly5.1<sup>+</sup>) DCs in wildtype and TCR $\delta$ <sup>-/-</sup> mice. However reduced proliferation of Ag specific CD8 T cells was observed in TCR $\delta$ <sup>-/-</sup>-OVA<sup>+/-</sup> (OVA Tg and  $\gamma\delta$  deficient) mice and in mice grafted with well-healed TCR $\delta$ <sup>-/-</sup>-OVA<sup>+/-</sup> skin. This coupled with lower CD40 levels on migrating DCs of TCR $\delta$ <sup>-/-</sup> mice may indicate a tolerogenic form of cross presentation resulting in poor cross-priming, a hypothesis which will be examined in further work. Various studies have reported that cross-presentation of self or cognate Ag by DCs not sufficiently activated by inflammatory stimuli can result in deletional T cell

tolerance (Kenna *et al.*, 2008; Waithman *et al.*, 2007). Furthermore due to the lack of growth factors, epidermal cells in TCR $\delta$ <sup>-/-</sup> mice go through three fold higher levels of apoptosis compared to wildtype (Sharp *et al.*, 2005). Considering the tolerogenic effects of apoptosing cells (Green *et al.*, 2009; Griffith *et al.*, 2007) it may be that cross-tolerance outweighs cross-priming to epidermal Ag in TCR $\delta$ <sup>-/-</sup> mice.

The significance of this study is the linking of  $\gamma\delta$  T cells to an augmented generation of CD8 T cell responses to cutaneous Ag. In line with this finding is a study showing that V $\gamma$ 1<sup>+</sup> cells recruited to the lungs of mice infected intranasally with Bacillus Calmette-Guerin (BCG) promote the development of CD8 cytotoxic T cells (Dieli *et al.*, 2003). Others have shown reduced levels of antibody or antibody producing plasma cells after mucosal OVA sensitization in the absence of  $\gamma\delta$  T cells (Fujihashi *et al.*, 1996; Svensson *et al.*, 2003). From a more broad perspective our study is in line with recent findings demonstrating a contribution by other innate cells e.g. NK cells, and NKT cells to cutaneous immunity in the context of skin transplantation and regulation of CD8 T cell immunity (Ito *et al.*, 2008; Kroemer *et al.*, 2008; Mattarollo *et al.*, 2010a; Mattarollo *et al.*, 2010b).

Characterization of  $\gamma\delta$  T cell involvement in the generation of adaptive immune responses in epithelia should facilitate development of immunotherapies utilizing  $\gamma\delta$  T cells in epithelial diseases including cancers and viral infections.

## MATERIALS AND METHODS

### Mice

C57BL/6 and congenic (Ly5.1<sup>+</sup>) Ptpcr mice were obtained from the Animal Resources Center (Perth, Australia). K5mOVA Tg mice expressing membrane-bound Ovalbumin driven from the K5 promoter were provided by H. Azukizawa (Osaka, Japan) (Azukizawa *et al.*, 2003). OT-I mice carrying a MHC-I restricted Tg TCR for OVA<sub>257-264</sub> (SIINFEKL), originally provided by F. Carbone (Melbourne, Australia) (Hogquist *et al.*, 1994) were crossed with (Ly5.1<sup>+</sup>) Ptpcr mice to generate mice bearing Ly5.1<sup>+</sup>OT-I cells. RAG/2C mice (a cross between RAG<sup>-/-</sup> and 2C Tg mice) were provided by B. Fazekas (Sydney, Australia) (Sha *et al.*, 1988). TCR $\delta$ <sup>-/-</sup> mice were obtained from Jackson Laboratory (Bar Harbor, USA). TCR $\delta$ <sup>-/-</sup> were crossed to K5mOVA mice, the F1 generation was backcrossed to TCR $\delta$ <sup>-/-</sup> to generate TCR $\delta$ <sup>-/-</sup>OVA<sup>+/-</sup> mice. The same breeding strategy was used to generate Ly5.1<sup>+</sup> TCR $\delta$ <sup>-/-</sup> congenic mice by crossing Ly5.1<sup>+</sup> Ptpcr mice with TCR $\delta$ <sup>-/-</sup> mice. All mice were bred under specific pathogen-free conditions at the Princess Alexandra Hospital Biological Research Facility. Age- and sex-matched animals of 6-10 week age were used in experiments. All animal procedures were approved by the University of Queensland Animal Ethics Committee.

### Reagents and flow cytometry

OVA<sub>257-264</sub> peptide, a H-2K<sup>b</sup> restricted CTL epitope with the amino acid sequence SIINFEKL was purchased from Auspep (Melbourne, Australia) with >80% purity, dissolved in 100% DMSO and stored at -20°C.

Anti-mouse monoclonal antibodies (mAb) to CD3 (145-2C11), CD8 (53-6.7), CD45.1 (A20), TCR-V $\alpha$ 2 (B20.1), MHC-II (M5/114.15.2), CD11c (N418) and CD40 (HM40-3) and associated isotype control immunoglobulins were purchased from BD Biosciences (San Jose, CA), eBioscience (San Diego, CA). Prior to antibody staining, Fc block (Fc $\gamma$  III/II receptor; BD Biosciences) was added to the cell suspension for 10 minutes on ice. Stained samples were analysed on FACSCalibur flow cytometer (BD Biosciences).

### Skin transplantation

Skin from donor mice was transplanted onto the flank of recipient mice as previously described (Dunn *et al.*, 1997; Matsumoto *et al.*, 2004). Briefly, donor skin was taken from the dorsal and ventral surfaces of the ear (~1cm<sup>2</sup>) and placed onto the thoracic flank region of anaesthetized recipients. Grafts were held in place with antibiotic-permeated gauze (Bactigras; Smith and Nephew, London, U.K.) and bandaged with micropore tape and Flex-wrap (Lyppard, Queensland, Australia). Bandages were removed 7 days post-grafting and grafts were monitored daily for loss of distinct border and signs of ulceration or necrosis to >80% of the graft which was used to define graft rejection.

### Preparation of single cells suspension from skin for flow cytometry

Naïve or grafted ear skin was digested by floating dermis side down in 1 mg/ml collagenase/dispase solution (Roche, Berlin, Germany) for 1 h at 37°C. At the end of the incubation epidermal sheets were separated from dermis using forceps and transferred into complete RPMI 1640 medium containing 10% FCS and disrupted by vigorous pipetting with a transfer pipette. Cells were then washed through a 70 micron cell strainer (BD Biosciences).

### In vivo assays and immunizations

To assess the proliferation of OVA specific CD8<sup>+</sup> T cells in vivo, Ly5.1<sup>+</sup> OT-I splenocytes were labelled with 2.5  $\mu$ M CFSE and injected I.V (5 $\times$ 10<sup>6</sup>) into the tail vein of OVA immunized, OVA Tg or OVA grafted wildtype and  $\gamma\delta$  T cell deficient mice. Respectively, 7 days and 42 hours after transfer into OVA immunized, OVA transgenic or OVA grafted mice, spleens and lymph nodes were harvested and CFSE dilutions in CD45.1<sup>+</sup> V $\alpha$ 2<sup>+</sup> CD8<sup>+</sup> were assessed by FACS. When taking skin DLNs, brachial, axillary and inguinal lymph nodes were harvested based on their proximity to skin grafts and increased size compared to uninvolved, contralateral lymph nodes. Proliferation indices were calculated using ModFit LT software (Verity Software House, Topsham, ME). 1  $\times$  10<sup>3</sup> in vitro activated OT-I cells, provided by T. Kenna (Kenna *et al.*, 2010) were injected I.V via the tail vein into RAG2/C mice. To evaluate immune responses to soluble Ag, mice were immunized subcutaneously in the tail base with 50  $\mu$ g OVA (Grade 5; Sigma-Aldrich, St. Louis, MO) and 20  $\mu$ g QuilA adjuvant (Soperfos Biosector DK-Vedback, Denmark). Negative control mice were immunized with 20  $\mu$ g QuilA only.

### IFN- $\gamma$ ELISPOT

ELISPOT assays were performed as previously described (Narayan *et al.*, 2007). Briefly, cells from spleens of OVA immunized or OVA grafted mice were cultured overnight in complete RPMI 1640 medium in the presence of 5 ng/ml recombinant mouse IL-2 (BD



Biosciences) and 0.1  $\mu\text{M}$  SIINFEKL peptide in ELISPOT assays. IFN- $\gamma$  spot-forming units were counted using an ELISPOT plate reader and stipulated as SFU per  $5 \times 10^5$  splenocytes.

### In vivo CD8 T cells depletion

CD8 T cells were depleted by intraperitoneal administration of anti-CD8 $\beta$  depleting antibody (clone 53-5.8) at days -2, 0 and +7 relative to skin transplantation using 100  $\mu\text{g}$ , 100  $\mu\text{g}$  and 150  $\mu\text{g}$  mAb per mouse at each time point respectively. Equal amount of purified rat serum (isotype control) was injected into control mice. Two days after the last injection (Day +9) mice were eye-bled and tested for efficacy of depletion, which was consistently greater than 98%.

### FITC painting

Flank skin was shaved with clippers and painted with 50  $\mu\text{l}$  of 5 mg/ml FITC solution in 1:1 in acetone: dibutylphthalate (Sigma-Aldrich, St. Louis, MO). DLNs were harvested 4 days after painting and analyzed by FACS for MHC-II<sup>hi</sup> CD11c<sup>hi</sup> FITC<sup>+</sup> cells (migrating DCs). In the case of painting grafted mice, bandages were removed from mice 4 days post grafting and mice were painted on the graft at day 5 post grafting with 10  $\mu\text{l}$  of 25 mg/ml FITC solution.

### Statistics

Kaplan-Meier plots were used to analyze skin graft survival and a log-rank test was performed to assess the statistical significance of differences between survival curves. For all other data in which statistics were performed, a two-tailed, nonparametric Mann-Whitney test was used for assessment of differences between groups. Differences with a  $p$  value of  $<0.05$  were considered to be significant. Prism (Graphpad Software, La Jolla, CA) was used for graphs and statistical analysis.

### Acknowledgments

The authors thank Dr. Tony Kenna for providing *in vitro* activated OT-I cells, Sean Smith for mouse genotyping, Allison Choyce for technical support and staff at the Biological Research Facility at Princess Alexandra Hospital for technical support and animal care.

**Financial Support:** This work was supported by program grant 080214 from the National Health and Medical Research Council of Australia, NCI grant RFA-CA-08-018, and funding from the Australian Cancer Research Foundation and the Lions Medical Research Foundation. A.R. was recipient of a postgraduate “UQ PhD Confirmation Scholarship” and I.H.F. was recipient of Queensland Government Premiers Fellowship.

### References

- Allison JP, Havran WL. The immunobiology of T cells with invariant gamma delta antigen receptors. *Annu Rev Immunol.* 1991; 9:679–705. [PubMed: 1832874]
- Azukizawa H, Kosaka H, Sano S, Heath WR, Takahashi I, Gao XH, et al. Induction of T-cell-mediated skin disease specific for antigen transgenically expressed in keratinocytes. *Eur J Immunol.* 2003; 33:1879–88. [PubMed: 12811848]
- Boismenu R, Feng L, Xia YY, Chang JC, Havran WL. Chemokine expression by intraepithelial gamma delta T cells. Implications for the recruitment of inflammatory cells to damaged epithelia. *J Immunol.* 1996; 157:985–92. [PubMed: 8757601]


- Broom JK, Lew AM, Azukizawa H, Kenna TJ, Leggatt GR, Frazer IH. Antigen-Specific CD4 Cells Assist CD8 T-Effector Cells in Eliminating Keratinocytes. *J Invest Dermatol.* 130:1581–9. [PubMed: 20147961]
- Chen Y, Chou K, Fuchs E, Havran WL, Boismenu R. Protection of the intestinal mucosa by intraepithelial gamma delta T cells. *Proc Natl Acad Sci U S A.* 2002; 99:14338–43. [PubMed: 12376619]
- D'Souza CD, Cooper AM, Frank AA, Mazzaccaro RJ, Bloom BR, Orme IM. An anti-inflammatory role for gamma delta T lymphocytes in acquired immunity to *Mycobacterium tuberculosis*. *J Immunol.* 1997; 158:1217–21. [PubMed: 9013962]
- Dieli F, Ivanyi J, Marsh P, Williams A, Naylor I, Sireci G, et al. Characterization of lung gamma delta T cells following intranasal infection with *Mycobacterium bovis* bacillus Calmette-Guerin. *J Immunol.* 2003; 170:463–9. [PubMed: 12496432]
- Dunn LA, Evander M, Tindle RW, Bulloch AL, de Kluyver RL, Fernando GJ, et al. Presentation of the HPV16E7 protein by skin grafts is insufficient to allow graft rejection in an E7-primed animal. *Virology.* 1997; 235:94–103. [PubMed: 9300040]
- Fujihashi K, McGhee JR, Kweon MN, Cooper MD, Tonegawa S, Takahashi I, et al. gamma/delta T cell-deficient mice have impaired mucosal immunoglobulin A responses. *J Exp Med.* 1996; 183:1929–35. [PubMed: 8666951]
- Girardi M, Oppenheim DE, Steele CR, Lewis JM, Glusac E, Filler R, et al. Regulation of cutaneous malignancy by gammadelta T cells. *Science.* 2001; 294:605–9. [PubMed: 11567106]
- Gorczynski RM. Adoptive transfer of unresponsiveness to allogeneic skin grafts with hepatic gamma delta + T cells. *Immunology.* 1994; 81:27–35. [PubMed: 8132216]
- Gorczynski RM, Chen Z, Fu XM, Levy G, Cohen Z. Gamma delta TCR+ cells regulate rejection of small intestinal allografts in rats. *Transplant Proc.* 1997; 29:863–4. [PubMed: 9123557]
- Gorczynski RM, Cohen Z, Levy G, Fu XM. A role for gamma(delta)TCR+ cells in regulation of rejection of small intestinal allografts in rats. *Transplantation.* 1996; 62:844–51. [PubMed: 8824487]
- Gray EE, Suzuki K, Cyster JG. Cutting edge: Identification of a motile IL-17-producing gammadelta T cell population in the dermis. *Journal of immunology.* 2011; 186:6091–5.
- Green DR, Ferguson T, Zitvogel L, Kroemer G. Immunogenic and tolerogenic cell death. *Nat Rev Immunol.* 2009; 9:353–63. [PubMed: 19365408]
- Griffith TS, Kazama H, VanOosten RL, Earle JK Jr, Herndon JM, Green DR, et al. Apoptotic cells induce tolerance by generating helpless CD8+ T cells that produce TRAIL. *J Immunol.* 2007; 178:2679–87. [PubMed: 17312109]
- Havran WL, Chien YH, Allison JP. Recognition of self antigens by skin-derived T cells with invariant gamma delta antigen receptors. *Science.* 1991; 252:1430–2. [PubMed: 1828619]
- Hayday AC. [gamma][delta] cells: a right time and a right place for a conserved third way of protection. *Annu Rev Immunol.* 2000; 18:975–1026. [PubMed: 10837080]
- Hogquist KA, Jameson SC, Heath WR, Howard JL, Bevan MJ, Carbone FR. T cell receptor antagonist peptides induce positive selection. *Cell.* 1994; 76:17–27. [PubMed: 8287475]
- Ito A, Shimura H, Nitahara A, Tomiyama K, Ito M, Kanekura T, et al. NK cells contribute to the skin graft rejection promoted by CD4+ T cells activated through the indirect allorecognition pathway. *International immunology.* 2008; 20:1343–9. [PubMed: 18697765]
- Jameson J, Havran WL. Skin gammadelta T-cell functions in homeostasis and wound healing. *Immunol Rev.* 2007; 215:114–22. [PubMed: 17291283]
- Jameson J, Ugarte K, Chen N, Yachi P, Fuchs E, Boismenu R, et al. A role for skin gammadelta T cells in wound repair. *Science.* 2002; 296:747–9. [PubMed: 11976459]
- Jameson JM, Cauvi G, Sharp LL, Witherden DA, Havran WL. Gammadelta T cell-induced hyaluronan production by epithelial cells regulates inflammation. *J Exp Med.* 2005; 201:1269–79. [PubMed: 15837812]
- Kaminski MJ, Cruz PD Jr, Bergstresser PR, Takashima A. Killing of skin-derived tumor cells by mouse dendritic epidermal T-cells. *Cancer Res.* 1993; 53:4014–9. [PubMed: 8358730]
- Kenna TJ, Thomas R, Steptoe RJ. Steady-state dendritic cells expressing cognate antigen terminate memory CD8+ T-cell responses. *Blood.* 2008; 111:2091–100. [PubMed: 18003887]

- Kenna TJ, Waldie T, McNally A, Thomson M, Yagita H, Thomas R, et al. Targeting antigen to diverse APCs inactivates memory CD8+ T cells without eliciting tissue-destructive effector function. *J Immunol.* 2010; 184:598–606. [PubMed: 19995901]
- Kim J, Chang CK, Hayden T, Liu FC, Benjamin J, Hamerman JA, et al. The activating immunoreceptor NKG2D and its ligands are involved in allograft transplant rejection. *J Immunol.* 2007; 179:6416–20. [PubMed: 17982029]
- King DP, Hyde DM, Jackson KA, Novosad DM, Ellis TN, Putney L, et al. Cutting edge: protective response to pulmonary injury requires gamma delta T lymphocytes. *J Immunol.* 1999; 162:5033–6. [PubMed: 10227967]
- Klein J. Biology of the mouse histocompatibility-2 complex. Principles of immunogenetics applied to a single system. *Biology of the mouse histocompatibility-2 complex Principles of immunogenetics applied to a single system.* 1975; xii:620.
- Kroemer A, Xiao X, Degauque N, Edtinger K, Wei H, Demirci G, et al. The innate NK cells, allograft rejection, and a key role for IL-15. *J Immunol.* 2008; 180:7818–26. [PubMed: 18523245]
- Lakkis FG, Arakelov A, Konieczny BT, Inoue Y. Immunologic ‘ignorance’ of vascularized organ transplants in the absence of secondary lymphoid tissue. *Nat Med.* 2000; 6:686–8. [PubMed: 10835686]
- Matsue H, Cruz PD Jr, Bergstresser PR, Takashima A. Profiles of cytokine mRNA expressed by dendritic epidermal T cells in mice. *J Invest Dermatol.* 1993; 101:537–42. [PubMed: 8409520]
- Matsumoto K, Leggatt GR, Zhong J, Liu X, de Kluyver RL, Peters T, et al. Impaired antigen presentation and effectiveness of combined active/passive immunotherapy for epithelial tumors. *J Natl Cancer Inst.* 2004; 96:1611–9. [PubMed: 15523090]
- Mattarollo SR, Rahimpour A, Choyce A, Godfrey DI, Leggatt GR, Frazer IH. Invariant NKT cells in hyperplastic skin induce a local immune suppressive environment by IFN-gamma production. *J Immunol.* 2010a; 184:1242–50. [PubMed: 20028654]
- Mattarollo SR, Yong M, Tan L, Frazer IH, Leggatt GR. Secretion of IFN-gamma but not IL-17 by CD1d-restricted NKT cells enhances rejection of skin grafts expressing epithelial cell-derived antigen. *J Immunol.* 2010b; 184:5663–9. [PubMed: 20410490]
- Mombaerts P, Arnoldi J, Russ F, Tonegawa S, Kaufmann SH. Different roles of alpha beta and gamma delta T cells in immunity against an intracellular bacterial pathogen. *Nature.* 1993; 365:53–6. [PubMed: 8361537]
- Mukasa A, Hiromatsu K, Matsuzaki G, O’Brien R, Born W, Nomoto K. Bacterial infection of the testis leading to autoaggressive immunity triggers apparently opposed responses of alpha beta and gamma delta T cells. *J Immunol.* 1995; 155:2047–56. [PubMed: 7636256]
- Narayan S, Choyce A, Fernando GJ, Leggatt GR. Secondary immunisation with high-dose heterologous peptide leads to CD8 T cell populations with reduced functional avidity. *Eur J Immunol.* 2007; 37:406–15. [PubMed: 17274003]
- Nitahara A, Shimura H, Ito A, Tomiyama K, Ito M, Kawai K. NKG2D ligation without T cell receptor engagement triggers both cytotoxicity and cytokine production in dendritic epidermal T cells. *J Invest Dermatol.* 2006; 126:1052–8. [PubMed: 16484989]
- Roberts SJ, Smith AL, West AB, Wen L, Findly RC, Owen MJ, et al. T-cell alpha beta + and gamma delta + deficient mice display abnormal but distinct phenotypes toward a natural, widespread infection of the intestinal epithelium. *Proc Natl Acad Sci U S A.* 1996; 93:11774–9. [PubMed: 8876213]
- Rosenberg AS, Mizuochi T, Sharrow SO, Singer A. Phenotype, specificity, and function of T cell subsets and T cell interactions involved in skin allograft rejection. *J Exp Med.* 1987; 165:1296–315. [PubMed: 2437237]
- Rosenberg AS, Singer A. Cellular basis of skin allograft rejection: an in vivo model of immune-mediated tissue destruction. *Annu Rev Immunol.* 1992; 10:333–58. [PubMed: 1590990]
- Sawada T, Wu Y, Sachs DH, Iacomini J. CD4+ T cells are able to reject class I disparate allografts. *Transplantation.* 1997; 64:335–40. [PubMed: 9256197]
- Sha WC, Nelson CA, Newberry RD, Kranz DM, Russell JH, Loh DY. Selective expression of an antigen receptor on CD8-bearing T lymphocytes in transgenic mice. *Nature.* 1988; 335:271–4. [PubMed: 3261843]


- Sharp LL, Jameson JM, Cauvi G, Havran WL. Dendritic epidermal T cells regulate skin homeostasis through local production of insulin-like growth factor 1. *Nat Immunol.* 2005; 6:73–9. [PubMed: 15592472]
- Shiohara T, Moriya N, Hayakawa J, Itohara S, Ishikawa H. Resistance to cutaneous graft-vs.-host disease is not induced in T cell receptor delta gene-mutant mice. *J Exp Med.* 1996; 183:1483–9. [PubMed: 8666906]
- Strid J, Roberts SJ, Filler RB, Lewis JM, Kwong BY, Schpero W, et al. Acute upregulation of an NKG2D ligand promotes rapid reorganization of a local immune compartment with pleiotropic effects on carcinogenesis. *Nat Immunol.* 2008; 9:146–54. [PubMed: 18176566]
- Sumaria N, Roediger B, Ng LG, Qin J, Pinto R, Cavanagh LL, et al. Cutaneous immunosurveillance by self-renewing dermal gammadelta T cells. *J Exp Med.* 2011; 208:505–18. [PubMed: 21339323]
- Svensson L, Lilliehook B, Larsson R, Bucht A. gammadelta T cells contribute to the systemic immunoglobulin E response and local B-cell reactivity in allergic eosinophilic airway inflammation. *Immunology.* 2003; 108:98–108. [PubMed: 12519308]
- Mak, Tak W.; S, ME. *The Immune Response Basic and Clinical Principles.* Vol. 1194. Elsevier Academic Press; San Diego: 2006.
- Waithman J, Allan RS, Kosaka H, Azukizawa H, Shortman K, Lutz MB, et al. Skin-derived dendritic cells can mediate deletional tolerance of class I-restricted self-reactive T cells. *J Immunol.* 2007; 179:4535–41. [PubMed: 17878350]
- Wu H, Wang YM, Wang Y, Hu M, Zhang GY, Knight JF, et al. Depletion of gammadelta T cells exacerbates murine adriamycin nephropathy. *J Am Soc Nephrol.* 2007; 18:1180–9. [PubMed: 17329577]
- Zhong J, Hadis U, De Kluyver R, Leggatt GR, Fernando GJ, Frazer IH. TLR7 stimulation augments T effector-mediated rejection of skin expressing neo-self antigen in keratinocytes. *Eur J Immunol.* 2008; 38:73–81. [PubMed: 18157820]

### Nonstandard abbreviations used


<b>DETC</b>	Dendritic Epidermal T cells
<b><math>\gamma\delta</math> T cell</b>	gamma delta T cells
<b>OVA</b>	Ovalbumin
<b>mAb</b>	monoclonal antibody
<b>DLNs</b>	Draining lymph nodes
<b>IV</b>	Intravenous
<b>SC</b>	Subcutaneous
<b>Tg</b>	Transgenic
<b>Ag</b>	Antigen
<b>FACS</b>	Flow cytometry



**Figure 1. Skin resident  $\gamma\delta$  T cells enhance rejection of OVA expressing skin grafts**  
 (A) Graft survival for K5mOVA (n=19), C57 (n=10), TCR $\delta^{-/-}$ -OVA $^{+/-}$  (n=10) and TCR $\delta^{-/-}$  (n=19) grafts transplanted onto C57 and TCR $\delta^{-/-}$  recipients. (\*\*: P < 0.01) (B) Graft survival for K5mOVA grafts transplanted onto C57 (n=10) or TCR $\delta^{-/-}$  (n=15) recipients (P = N.S) and TCR $\delta^{-/-}$ -OVA $^{+/-}$  grafts transplanted onto C57 (n=13) recipients. (C) Graft survival for TCR $\delta^{-/-}$ -OVA $^{+/-}$  grafts transplanted onto TCR $\delta^{-/-}$  animals, recipient of  $1 \times 10^8$  splenocytes from TCR $\delta^{-/-}$  (n=5) or C57 (n=5) mice, or without transferred splenocytes (n=5) (P = N.S.). (Graft survival curves were assessed for significance using Kaplan-Meier survival analysis).




**Figure 2. Graft priming, but not systemic priming to OVA is impaired in  $TCR\delta^{-/-}$  mice**  
 (A) C57 (n=7) and  $TCR\delta^{-/-}$  (n=8) mice were grafted with K5mOVA and  $TCR\delta^{-/-}$ -OVA $^{+/-}$  skin respectively. Controls mice were immunized with OVA + QuilA or QuilA only. 20 days later SIINFEKL specific  $IFN\gamma$  producing CD8 T cells from the spleen was assessed (\*\*:  $P < 0.01$ ) (B) C57 (n=7) and  $TCR\delta^{-/-}$  mice (n=7) mice were grafted with  $TCR\delta^{+/-}$ -OVA $^{+/-}$  and  $TCR\delta^{-/-}$ -OVA $^{+/-}$  skin, respectively. All mice received CFSE labelled OT-I cells. 9 days later, OT-I cells proliferation in graft DLNs was analyzed (\*:  $P < 0.05$ ). (C) C57 and  $TCR\delta^{-/-}$  mice (n=4) immunized with OVA + QuilA or QuilA only. SIINFEKL specific  $IFN\gamma$  secreting T cells were assessed in the spleen after 7 days ( $P = N.S$ ). (D) T cell proliferation in DLN of  $TCR\delta^{-/-}$  and C57 mice recipient of CFSE labeled OT-I cells and immunized with QuilA or OVA + QuilA, was assessed after 4 days ( $P = N.S$ ). FACS histograms show representative CFSE dilution. (Un-paired t test was used for statistical analysis).



**Figure 3. Effector functions of CD8 T cells required for graft rejection are not measurably impaired by the absence of  $\gamma\delta$  T cells**


(A) Graft survival for K5mOVA (n=8) and TCR $\delta^{-/-}$ -OVA $^{+/-}$  (n=8) grafts, transplanted respectively onto C57 and TCR $\delta^{-/-}$  mice immunized with OVA + QuilA (P= N.S) (B) Graft survival for K5mOVA or TCR $\delta^{-/-}$ -OVA $^{+/-}$  (n=8) grafts, transplanted separately onto 2C TCR Tg Rag $^{-/-}$  mice transferred with  $1 \times 10^3$  in vitro activated OT-I cells (P=N.S). (Graft survival curves were assessed for significance using Kaplan-Meier survival analysis).



**Figure 4. Impaired OT-I proliferation to skin derived OVA in steady state**

(A) TCR $\delta^{+/-}$ OVA $^{+/-}$  (n=5), TCR $\delta^{-/-}$ OVA $^{+/-}$  (n=5) and non-Tg mice received CFSE labelled OT-I cells. Control non-Tg mice were immunized with OVA+QuilA. DLN cells were assessed OT-I proliferation in DLNs was assessed 42 hours later (\*\*: P < 0.01). (B) Graft survival for TCR $\delta^{+/-}$ OVA $^{+/-}$  (n=16) and TCR $\delta^{-/-}$ OVA $^{+/-}$  (n=16) grafts transplanted onto CD8 depleted, C57 and TCR $\delta^{-/-}$  mice respectively (\*\*: P < 0.01). (C) Mice [from Fig 4B] that failed to reject OVA grafts received CFSE labelled OT-I cells. Proliferation in graft DLNs was assessed after 42 hours. (\*\*: P < 0.01). FACS histograms show representative CFSE dilution. (Un-paired t test was used for proliferation indices and Kaplan-Meier survival analysis for graft survival curves).





**Figure 5. CD40 levels on migrating DCs and not DC migration is impaired in TCR $\delta^{-/-}$  mice** (A) C57 and TCR $\delta^{-/-}$  mice, grafted with syngeneic skin, or non-grafted were painted with FITC on graft site or a corresponding site on non-grafted mice. 4 days later, DLNs were analysed for FITC<sup>+</sup> migrating DC as a percentage of all DC (P= N.S) (B) Graft DLNs of C57 (n=4) and TCR $\delta^{-/-}$  (n=4) mice grafted with congenic Ly5.1<sup>+</sup> skin grafts were analysed 4 days later for Ly5.1<sup>+</sup> migrating DC as a percentage of all DC (P= N.S) (C) CD40 expression on migrating DC in skin DLNs cells from grafted or non-grafted C57 and TCR $\delta^{-/-}$  mice (\*\*: P < 0.01; unpaired t test). Histogram shows representative isotype and CD40 staining on migrating DCs.